Cite

HARVARD Citation

    Mato, A. et al. (n.d.). Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial. American journal of hematology. 93 (11), pp. 1394-1401. [Online]. 
  
Back to record